Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Crizotinib

e133cdc4-3f7a-527c-b9e1-1d9c7a82cbff · FDA Approved · targets ALK, ROS_ROS1

Crizotinib

MeasuredReference

Crizotinib targets EPHA6, ROS_ROS1, RON_MST1R. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

EPHA6ROS_ROS1RON_MST1RLIMK1JAK2

Top hallmarks

  • tumor promoting inflammation5.4k
  • evading apoptosis3.7k
  • proliferation3.7k

Top pathways disrupted

  • allograft rejection9.8k
  • pi3k akt mtor signaling9.1k
  • apical junction9.1k

Resistance landscape — Crizotinib

MeasuredReference

1 known oncogenic variants exist on Crizotinib's top targets — see detail for inhibition impact.

Open in new tab